Business Context and Reporting Period
This Form 8-K Current Report was filed by Adial Pharmaceuticals, Inc. on July 8, 2019, covering events occurring on July 5, 2019. The Company is a Delaware corporation focused on the development of AD04, an investigational new drug for the treatment of alcohol use disorder. The filing primarily addresses the entry into a material definitive agreement to support an upcoming Phase 3 clinical trial.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed relates to the compensation for a new service agreement:
- Agreement Compensation: Approximately $300,000 total.
- Equity Component: 20% of the fees (approximately $60,000 in value) will be paid in Company common stock.
- Cash Component: The remaining 80% is implied to be paid in cash, though the filing text does not explicitly state the cash portion amount.
Material Changes and Related Party Transaction
The Company entered into a Master Services Agreement (MSA) with Psychological Education Publishing Company (PEPCO) to administer a behavioral therapy program (Brief Behavioral Compliance Enhancement Treatment or BBCET) for the Phase 3 trial of AD04. This is a related party transaction as PEPCO is owned by an affiliate of the Company, Dr. Bankole Johnson, who serves as the Chief Medical Officer and is the Company's largest stockholder.
- Termination Rights: The Company may terminate the MSA with 10 days' prior written notice or immediately for cause/violation of provisions.
- Duration: The statement of work terminates upon the completion and delivery of the final study report for the Trial.
Guidance, Risks, and Unusual Items
The filing does not provide updated financial guidance or general outlook commentary. However, it details specific terms and restrictions regarding the equity compensation:
- Stock Issuance: Shares issued to Dr. Johnson are subject to the Company's 2017 Equity Incentive Plan and require Nasdaq Capital Market approval.
- Lock-Up Period: The issued shares are subject to a six-month lock-up period from the date of issuance, during which Dr. Johnson cannot sell, pledge, or transfer the shares.
- Restrictions: Stock certificates will bear a restrictive legend, and book-entry shares will have a restricted notation.
Investor Verification Checklist
- Verify the approval status of the Nasdaq Capital Market for the issuance of shares to Dr. Johnson.
- Confirm the exact valuation of the common stock used to calculate the 20% equity portion of the $300,000 fee.
- Review the full text of the Master Services Agreement (Exhibit 10.1) for specific performance milestones and payment schedules.
- Monitor the progress of the Phase 3 clinical trial for AD04, as the agreement's duration is tied to the trial's completion.